Compare HGBL & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HGBL | ELUT |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 41.9M |
| IPO Year | 1998 | 2020 |
| Metric | HGBL | ELUT |
|---|---|---|
| Price | $1.21 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.85 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 88.2K | 56.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $20,129,000.00 | $12,293,000.00 |
| Revenue This Year | $11.92 | N/A |
| Revenue Next Year | $13.52 | $10.83 |
| P/E Ratio | $60.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $0.50 |
| 52 Week High | $2.20 | $2.50 |
| Indicator | HGBL | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 44.57 |
| Support Level | $1.19 | $0.88 |
| Resistance Level | $1.28 | $1.18 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 33.33 | 36.43 |
Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It operates in four segments. The Auction and Liquidation segment, which operates as a full-service auction, appraisal, and asset advisory firm, includes the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment. The Refurbishment & Resale segment acquires, refurbishes, and supplies specialized laboratory equipment. Brokerage segment, through NLEX, brokers charged-off receivables in the U.S. and Canada on behalf of financial institutions. The Specialty Lending segment, which provides specialty financing solutions to investors in charged-off and nonperforming asset portfolios.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.